Approximately 15–20% of breast cancers overexpress HER2, and nearly half of HER2+ breast cancers also express hormone receptors (HRs), such as estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) [2]. This evidence concerns the gene ERBB2 and breast carcinoma.